评估喘患者的数字坚持支持:ADITION非干预性研究
Holger Woehrle1, Jens Driemert2, Lukas Jerrentrup3
1Lungenzentrum Ulm, Ulm, Germany.
ERJ open research
|March 5, 2025
概括
对喘维持治疗的数字支持与没有支持相比,显示了类似的喘控制改善. 这项研究强调了评估数字工具对吸入器在真实世界喘管理中的坚持的挑战.
科学领域:
- 呼吸系统医学 呼吸系统医学
- 数字健康数字健康
- 药物经济学 药物经济学
背景情况:
- 对喘维持治疗的不良遵守会对患者的结果产生负面影响.
- 数字依从性支持系统为改善药物依从性提供了一个潜在的解决方案.
- 这项研究调查了数字支持在喘管理中的作用.
研究的目的:
- 为了评估使用mometasone furoate/indacaterol/glycopyrronium (MF/IND/GLY) 的患者的喘控制和坚持.
- 为了将这些结果与使用任何吸入性皮质类固醇/长效β2激动剂/长效肌抗体 (ICS/LABA/LAMA) 组合而没有数字支持的患者进行比较.
主要方法:
- 在德国对成人喘患者进行前性,非干预性,多中心的开放性研究.
- 主要终点:6个月后喘控制测试 (ACT) 得分的变化.
- 倾向性得分匹配被用来比较群体之间的结果.
主要成果:
- 在倾向匹配后,MF/IND/GLY与数字支持组和单独的ICS/LABA/LAMA组之间在ACT得分改善方面没有显著差异.
- 在这两组中,在整个研究过程中观察到的适度基线坚持和有限的变化.
- 在两个治疗臂中,不良事件的发生率相似.
结论:
- 使用数字支持的莫马塔松酸/英达卡特/甘皮龙提供了与标准ICS/LABA/LAMA治疗相比的喘控制.
- 合规性显示出最小的变化,这表明改善对当前数字工具的合规性存在挑战.
- 需要进一步的研究来优化数字支持系统,以提高喘息患者吸入器粘附度.
相关概念视频
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:30Asthma-IV: Nursing Management
2.9K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
First, in...
2.9K
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
2.5K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
2.5K
01:23Inhaled Medications
218
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
218
01:26COPD: Management Using Bronchodilators and Corticosteroids
170
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
170
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
224
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
224